21 results about "Drug allergy" patented technology

The invention relates to an intelligent diagnosis and treatment method and system based on a knowledge graph and a large language model. The method comprises the steps of constructing a basic framework of a medical field knowledge graph based on collected medical field data, constructing multi-level knowledge graph expression, obtaining symptom description of a patient through multiple rounds of dialogues, diagnosing the patient and generating a diagnosis report, rechecking and adjusting the diagnosis report by a professional physician, and finally outputting the diagnosis report. The intelligent diagnosis and treatment system comprises a knowledge graph construction module, an intelligent question and answer system, an entity matching module, an intelligent diagnosis module, a doctor review and diagnosis report adjustment module, a diagnosis report output module and the like. And main diseases are screened, so that the coverage is wider. And three levels of knowledge maps are constructed, so that text matching with finer granularity can be carried out. The non-standardized expression of the patient is firstly converted into standardized medical terms through a large model, and drug allergy and the like are taken into consideration, so that the diagnosis accuracy is improved, and the diagnosis and treatment risk is reduced.

The invention relates to the technical field of medical data processing, in particular to an AI-based anorectal operation auxiliary system, which comprises a patient health data analysis module, a patient health data analysis module, a data processing module, a data processing module, a data processing module, a data processing module, a data processing module and a data processing module, wherein the patient health data analysis module is used for classifying personal information of a patient and health data associated with anorectal diseases on the basis of basic physiological parameters of the patient, past anorectal disease history, medicine allergy history and operation records; and performing correlation analysis on the anorectal disease history and the physiological parameters of the patient to generate preoperative health feature information. According to the method, the physiological parameters of the patient and the past medical history are subjected to correlation analysis, key health indexes related to the operation can be accurately extracted, potential relations in the data can be mined, and the application effect of the data is optimized. By analyzing the combination mode of different health data, the probability of occurrence of common risks in the operation can be predicted, and the accuracy of medical decision making is enhanced. In addition, key operation steps of the surgery are matched with the health state of the patient, potential operation difficulties are recognized, and the scheme is optimized in a targeted mode.

The invention discloses a luminescent cell for rapidly detecting drug allergy and / or anaphylactoid reaction as well as a construction method and application of the luminescent cell, and relates to the technical field of biology. The construction method comprises the following steps: transforming myeloid related cells by using a recombinant vector containing a marker gene and an HHEXA gene promoter to obtain recombinant cells; the recombinant cell is the luminescent cell. According to the invention, the HHEXA gene promoter and the marker gene are recombined and then transferred into myeloid related cells, and the occurrence of the allergy or anaphylactoid reaction can be intuitively reflected through a marker signal by utilizing the specific activation characteristic of the HHEXA gene in the allergy / anaphylactoid reaction. The luminescent cell has good stability, is suitable for multiple scenes such as drug allergy, anaphylactoid risk assessment, environmental sample analysis and the like, provides an efficient, sensitive and convenient technical tool for clinical rapid diagnosis, new drug research and development and scientific research and exploration, and can significantly reduce the detection cost and the operation threshold.

The invention discloses an application of a nitrobenzene-containing urea compound in preparation of an anti-allergic reaction drug, and the nitrobenzene-containing urea compound can be applied in preparation of a drug for antagonizing mouse sole swelling and plasma exosmosis caused by C48 / 80. The invention also discloses application of the compound in preparation of drugs for antagonizing mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80. The nitrobenzene-containing urea compound can effectively relieve mouse sole swelling and plasma exosmosis, mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80, reduce serum histamine release and relieve body temperature decline, so that the occurrence of anaphylactoid reaction is inhibited, and the nitrobenzene-containing urea compound can be used for preventing and treating hyperplasia. Therefore, when the nitrobenzene-containing urea compound is used as an anti-drug anaphylaxis preparation, more possible treatment schemes are provided for clinical drug anaphylaxis treatment.

The utility model provides identification clothes facilitating management of psychopath, which comprise an identification clothes body, a plurality of cloth rings arranged on one side of the shoulder of the identification clothes body, signboards arranged on the cloth rings through buckles, a first transparent storage bag arranged corresponding to the signboards and an identification card arranged on the identification clothes body. The identification card comprises an identification piece and a hook-and-loop fastener arranged on one side of the identification piece, and a hook-and-loop fastener corresponding to the hook-and-loop fastener is arranged on the front clothes part. The cloth rings are arranged on the shoulders of the identification clothes body, then the signboards are arranged on the cloth rings through the buckles, and meanwhile the first transparent storage bag is arranged on one side of the identification clothes body to store the signboards, so that the identification clothes are not prone to being lost, and nursing staff can observe and manage the identification clothes conveniently; the identification card is arranged through the hook-and-loop fastener, so that information such as the medicine allergy history of the patient can be recorded conveniently, daily management of nursing personnel is facilitated, and safety accidents are reduced.

The utility model discloses a medicine allergy prompting disc, which relates to the technical field of medical instruments and comprises a shell, a display disc is arranged in the shell, an observation port is arranged on the shell, a limiting ring is arranged in the shell, the limiting ring is rotatably connected with a rotating shaft, and the rotating shaft is fixedly connected with the central position of the display disc. Through the arrangement of the display panel and the observation opening, eight groups of allergic drug areas are arranged on the display panel in an array mode, different types of allergic drugs are recorded in each group of areas, and when a treatment post nurse is reminded of allergic conditions of a patient and the allergic drugs are prompted through the drug allergy prompting panel, the rotating shaft rotates in the limiting ring, so that the allergic drugs are prompted to the patient through the drug allergy prompting panel; after an area for recording allergic drugs of a patient is rotated to an observation opening, a treatment post nurse can be reminded of the drug allergy type of the patient, medical negligence caused by wrong use of drugs is avoided, safety is improved, and practicability of the drug allergy prompting disc is improved.

To solve the problem in medicine selection by displaying the suitability of a medicine suitable for an individual with % on the basis of the current symptoms, and taking past medical records and a risk of unpredictable medicine allergy onset.SOLUTION: A system includes means for displaying the suitability of a medicine suitable for an individual with % on the basis of the current symptoms, means for determining a case that cannot be used with reference to past medical records, and means for evaluating a risk of an unpredictable medicine allergy onset.SELECTED DRAWING: Figure 1

The invention provides a medical supervision platform. A patient personal information base and a pathology big database are established; the doctor inquires the patient according to the information of the patient information base and makes corresponding diagnosis; the supervision module compares and checks the diagnosis content of the proofreading doctor through big data; after checking, doctor diagnosis is input into a patient information base, and corresponding medical resources are allocated; the patient personal information base comprises basic information of patients, past medical history, medicine allergy history, examination results and uncomfortable symptoms, the pathology big database comprises disease names, disease indications, medicine principles and treatment modes, the platform can improve the accuracy and rationality of medical diagnosis, and by checking a medicine treatment scheme of a doctor, the medical diagnosis accuracy and rationality can be improved. And the treatment mode, the medicine type and the dosage are ensured to meet medical standards and patient requirements. The proofreading steps are helpful for reducing the risk of drug treatment and improving the treatment effect of patients.

The application belongs to the technical field of biological medicine, and particularly relates to a binding molecule targeting CCL5 and application of the binding molecule in combination with drugs in treatment of Th2-type inflammation related diseases. The application discloses use of a binding molecule targeting CCL5 or a pharmaceutical composition comprising the binding molecule in preparation of a product having one or more of the following functions: 1) prevention and / or treatment of Th2-type inflammation related diseases; 2) reduction of skin lesion tissue thickness; 3) reduction of clinical score of atopic dermatitis; 4) reduction of scratching behavior; 5) reduction of tissue damage; 6) alleviation of inflammatory reaction and inhibition of expression of inflammatory factors; and 7) reduction of inflammatory cell infiltration. The binding molecule targeting CCL5 or the pharmaceutical composition comprising the binding molecule has important value in prevention and treatment of immune inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy or drug allergy.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of a compound in preparation of an anti-allergic reaction medicine. The compound provided by the invention can effectively inhibit mast cell degranulation so as to inhibit generation of IgE-mediated I-type anaphylaxis, so that the compound is used as an anti-drug anaphylaxis preparation to provide more possible treatment schemes for clinical drug anaphylaxis treatment.

1. The name of the design product: three seals. 2. The use of the design product: The three sides of the seal are GBS (+), antibiotic and drug allergy words, and the animal footprint on the side helps understanding. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The invention provides a model for predicting the risk of allergic reaction of a Wilson disease patient during copper expelling treatment, and belongs to the crossing field of clinical medicine and biological information technology. The risk prediction model comprises: an input module receiving patient parameter indexes composed of a sodium dimercaptopropanesulfonate injection dosage, a severe adverse drug reaction, a drug allergy history, a neutrophil count, a lymphocyte count, a ratio of neutrophil to lymphocyte, a ratio of platelets to lymphocyte, a leukocyte count, a urine copper level and a platelet count; the processing module is connected with the input module and is used for calculating the score and prediction probability of the allergic reaction during copper expelling treatment based on the parameter indexes of the patient; and the output module is connected with the processing module, and outputs the allergic reaction risk probability obtained by the risk prediction model during the copper expelling treatment of the Wilson disease patient. The risk prediction model can be conveniently used for early recognition and risk prediction of anaphylaxis of a Wilson disease patient during copper expelling treatment.

The invention discloses a drug sensitivity test drug recommendation system, method and device based on an AI large model and a medium, relates to the technical field of drug sensitivity tests, is applied to a computer device, and comprises a medical object information collection module used for collecting medical feature information from initial medical information of a medical object by using a feature information extraction AI large model; the medical feature information comprises basic information of a medical object, current and past drug allergy information and disease information; the drug recommendation module is used for determining a preliminary drug recommendation result according to a drug sensitive test result of the medical object and a preset expert database constructed based on a drug use industry standard; the medication recommendation module is used for inputting the medical feature information, the preliminary medication recommendation result and a medication database into a medication recommendation AI large model and outputting a target medication recommendation conclusion; the target drug use recommendation conclusion at least comprises recommended drugs, drug use risk information of the recommended drugs and drug use details. And more accurate and practical drug recommendation is realized.

1. The name of the design product: electronic device health history information display graphical user interface. 2. The use of the design product: an electronic device. 3. The design points of the design product: in the graphical user interface. 4. The picture or photo that best indicates the design points: interface change state diagram 1. 5. Other views are conventional designs, and other views are omitted. 6. The use of the graphical user interface: the interface of the design product is a graphical user interface for listing and displaying the health history information of the patient's health record, such as past medical history, drug allergy history, surgical history, and family history, of the elderly robot. 7. The human-computer interaction mode of the graphical user interface: the main view is the home page graphical user interface applied by the user; in the main view, click the "health record" button in the interface to enter interface change state diagram 1; in interface change state diagram 1, click the "health history" button in the interface to enter interface change state diagram 2; in interface change state diagram 2, click the "past medical history" button in the interface to enter interface change state diagram 3; ×××× in the interface represents text and / or numbers and / or letters and / or symbols.

The invention discloses an intelligent medication management system for liver, gall and pancreas nursing, relates to the technical field of medication management, and improves the medication safety of patients. According to the invention, the association degree among the disease semantic information sets is obtained according to the liver, gall and pancreas disease cases, a liver, gall and pancreas case analysis network and a plurality of interaction chains are established, and a plurality of stage prescription paths are established according to the liver, gall and pancreas disease cases. Matching each stage prescription path with the interaction chain to obtain a corresponding calibration stage prescription path, and inputting the calibration stage prescription path and the real-time body state data into a liver, gall and pancreas case analysis network, so that the liver, gall and pancreas case analysis network outputs a plurality of calibration stage prescription paths, and screening the prescription paths in the calibration stage through the drug allergy information, and selecting one prescription path in the calibration stage by a diagnosis and treatment doctor for execution.

Provided herein are compounds of Formula I which are thymic stromal lymphopoietin (TSLP) or thymic stromal lymphopoietin receptor (TSLPR) inhibitory compounds, capable of disrupting the protein-protein interaction between TSLP and TSLPR. Compounds of Formula I and compositions thereof modulate activity or inhibit TSLP and TSLPR binding, and are useful for downregulating atopy-relevant pro-inflammatory cytokines. In particular, compounds of Formula I as described herein are useful in the treatment of skin disease, allergic asthma, allergic rhinitis, drug allergies, and food allergies. Furthermore, the compounds described herein are absorbed by the skin. (I)

Disclosed are a urea compound containing nitrobenzene, a preparation method therefor, and use thereof. The preparation method comprises: dissolving bis(trichloromethyl)carbonate in anhydrous tetrahydrofuran, adding a solution of 4-nitroaniline in tetrahydrofuran, stirring uniformly after dropwise addition is completed, then adding triethylamine, stirring uniformly, evaporating the solvent to dryness, adding a solution of 4-aminobenzotrifluoride in anhydrous tetrahydrofuran, and reacting at 45 °C for 3 h to obtain the urea compound containing nitrobenzene. The urea compound containing nitrobenzene can effectively alleviate the swelling and plasma extravasation of the soles of mice, and skin vasodilation and mast cell degranulation of the soles of mice, which are caused by C48 / 80, thereby inhibiting the occurrence of anaphylactoid reactions. Therefore, using the urea compound containing nitrobenzene as an anti-drug allergy formulation provides more possible treatment regimens for the clinical treatment of drug allergies.

This invention presents a novel approach that integrates pharmacogenomics with multi-dimensional factor analysis to improve the detection of drug allergies and the adjustment of drug dosages tailored to individual patients. Genetic differences between individuals directly affect the production of proteins involved in the processes of absorption, distribution, metabolism, and excretion (ADME) of drugs in the body. This study has developed an analytical system that not only considers genetic factors but also includes external factors that influence drug efficacy, such as lifestyle habits, herbal consumption, and the effects of polypharmacy. The developed system utilizes a scoring process derived from the analysis of multiple data sources, including genetic data, treatment history, lifestyle information, and other clinical data. These scores assist in clinical decision making by evaluating the risk of adverse drug reactions and recommending appropriate drug dosage adjustments for each patient. This approach enhances the accuracy and safety of drug therapy.

The invention discloses a nitrobenzene-containing urea compound and a preparation method and application thereof.The preparation method comprises the steps that bis (trichloromethyl) carbonate is dissolved in anhydrous tetrahydrofuran, a tetrahydrofuran solution of 4-nitroaniline is added, the mixture is stirred to be uniform after dropwise adding is completed, then triethylamine is added, the mixture is stirred to be uniform, and the nitrobenzene-containing urea compound is obtained; and drying the solvent by distillation, adding an anhydrous tetrahydrofuran solution of 4-aminotrifluorotoluene, and reacting at 45 DEG C for 3 hours to obtain the nitrobenzene-containing urea compound. The nitrobenzene-containing urea compound provided by the invention can effectively relieve mouse sole swelling and plasma exosmosis, mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80, so that the occurrence of anaphylactoid reaction is inhibited, and therefore, the nitrobenzene-containing urea compound can be used as an anti-drug anaphylactoid reaction preparation, so that the application range of the nitrobenzene-containing urea compound is widened. And more possible treatment schemes are provided for clinical drug anaphylactic reaction treatment.

The invention discloses a tumor chemotherapy patient vomit-stopping medication management method and a related device. The method comprises the following steps: constructing a comprehensive database containing chemotherapy drug vomit-inducing levels, patient risk factors and vomit-stopping drug information; establishing a patient physiological parameter baseline database containing blood routine, liver and kidney functions, electrolyte and electrocardiogram indexes of the patient; dynamically predicting CINV early warning information of the patient according to the comprehensive database; according to the CINV early warning information, the comprehensive database, the patient physiological parameter baseline database, the medicine allergy history of the patient and the medicine interaction information, a personalized antiemetic medicine treatment scheme is recommended; and sending the vomit-stopping medicine treatment scheme to the nursing mobile terminal to remind a clinical nurse to give a vomit-stopping medicine and record the administration time and the administration route. According to the therapeutic principle and the drug attribute, the appropriate antiemetic drug is matched, the antiemetic treatment scheme is provided, and clinical nurses are reminded to give the optimal interval time of the antiemetic drug in time so as to ensure the optimal curative effect of the antiemetic drug.

The application discloses a luminescent cell for rapidly detecting drug allergy and / or allergic reaction, and a construction method and application thereof, and relates to the technical field of biotechnology.The construction method comprises the following steps: transforming a myeloid-related cell with a recombinant vector containing a marker gene and an H_HEXA gene promoter to obtain a recombinant cell; and the recombinant cell is the luminescent cell.The application is characterized in that the H_HEXA gene promoter is recombined with the marker gene, and then is transformed into the myeloid-related cell, and the specific activation characteristics of the H_HEXA gene in the allergic reaction / allergic reaction are utilized, so that the occurrence of the allergic reaction or the allergic reaction can be directly reflected through a marker signal.The luminescent cell has good stability, is suitable for drug allergy, allergic reaction risk assessment, environmental sample analysis and other scenes, and provides an efficient, sensitive and convenient technical tool for clinical rapid diagnosis, new drug research and development and scientific research exploration, and can significantly reduce detection cost and operation threshold.